Boston Scientific announces participation in the J.P. Morgan Healthcare Conference and conference call discussing fourth quarter and full year 2025 results
Rhea-AI Summary
Boston Scientific (NYSE: BSX) will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 with a 40-minute Q&A starting at approximately 9:00 a.m. PT / 12:00 p.m. ET. Presenters include Mike Mahoney (chairman & CEO), Jon Monson (EVP & CFO) and Ken Stein, M.D. (SVP & global chief medical officer).
The company will also host a webcast conference call to discuss fourth quarter and full year results for the period ended December 31, 2025 on February 4, 2026 at 8:00 a.m. ET, preceded by a news release. Live webcasts and replays will be available at https://investors.bostonscientific.com, with replays posted about one hour after each event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, BSX declined 0.67%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Key medical device peers (SYK, MDT, EW, ABT, PHG) all show modest declines between about -0.47% and -0.91%, broadly similar to BSX’s -0.69% move, suggesting mild sector softness without strong momentum signals.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Management & product | Positive | +0.2% | New chairman at CathVision and ECGenius System Version 3.5 commercial release. |
| Nov 03 | Investor conferences | Neutral | -2.1% | Participation in Wolfe and Citi healthcare investor conferences announced. |
| Oct 22 | Q3 2025 earnings | Positive | +4.0% | Strong Q3 sales and EPS above guidance with raised 2025 outlook. |
| Oct 17 | Nalu acquisition | Positive | +1.5% | Agreement to acquire Nalu Medical to expand neuromodulation portfolio. |
| Sep 02 | Investor day & call | Neutral | +1.1% | Announcement of 2025 Investor Day and Q3 2025 earnings call timing. |
Recent company-specific news, especially earnings and M&A, has generally seen modestly positive price alignment, while scheduling and conference items have produced small, mixed moves.
Over the last few months, Boston Scientific news has focused on growth execution and investor engagement. Q3 2025 results on Oct 22 showed strong revenue and EPS with a 3.95% gain, and the Nalu Medical acquisition announcement on Oct 17 also drew a positive reaction. Earlier, the company outlined 2025 Investor Day and Q3 call logistics on Sep 2, with a smaller 1.1% move. Management and product updates at CathVision in Dec 2025 and a November conference schedule produced only slight price changes, indicating investors respond more strongly to concrete financial and strategic updates than to scheduling news.
Market Pulse Summary
This announcement outlines Boston Scientific’s participation in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 and schedules its Q4 and full-year 2025 earnings call for February 4, 2026 at 8:00 a.m. ET. It signals upcoming visibility into results and strategy but does not itself change fundamentals. Investors watching this type of news typically focus on the subsequent earnings release, management’s growth commentary, and any updated outlook once those details are provided.
Jargon Translator
AI-generated analysis. Not financial advice.
Additionally, the company will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year ended December 31, 2025, on Wednesday, February 4, 2026, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney and Jon Monson. The company will issue a news release announcing financial results for the fourth quarter and full year 2025 on February 4 prior to the conference call.
A live webcast and replay for each event will be accessible at https://investors.bostonscientific.com. The replay will be available approximately one hour following the completion of the event.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.
CONTACTS:
Emily Anderson
Media Relations
+1 (617) 515-2000
Emily.Anderson2@bsci.com
Lauren Tengler
Investor Relations
+1 (508) 683-4479
BSXInvestorRelations@bsci.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-announces-participation-in-the-jp-morgan-healthcare-conference-and-conference-call-discussing-fourth-quarter-and-full-year-2025-results-302648097.html
SOURCE Boston Scientific Corporation
FAQ
When will Boston Scientific (BSX) present at the J.P. Morgan Healthcare Conference?
Who will represent Boston Scientific (BSX) at the January 13, 2026 J.P. Morgan session?
When is Boston Scientific (BSX) releasing fourth quarter and full year 2025 results?
What time is the Boston Scientific (BSX) earnings conference call for Q4 and full year 2025?
Where can investors watch the Boston Scientific (BSX) J.P. Morgan presentation and earnings call webcast?
How soon after the events will Boston Scientific (BSX) post replays of the webcast?
